RU2017104799A3 - - Google Patents
Download PDFInfo
- Publication number
- RU2017104799A3 RU2017104799A3 RU2017104799A RU2017104799A RU2017104799A3 RU 2017104799 A3 RU2017104799 A3 RU 2017104799A3 RU 2017104799 A RU2017104799 A RU 2017104799A RU 2017104799 A RU2017104799 A RU 2017104799A RU 2017104799 A3 RU2017104799 A3 RU 2017104799A3
- Authority
- RU
- Russia
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Vascular Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462025371P | 2014-07-16 | 2014-07-16 | |
| US62/025,371 | 2014-07-16 | ||
| US201462043167P | 2014-08-28 | 2014-08-28 | |
| US62/043,167 | 2014-08-28 | ||
| US201462080725P | 2014-11-17 | 2014-11-17 | |
| US62/080,725 | 2014-11-17 | ||
| US201562132709P | 2015-03-13 | 2015-03-13 | |
| US62/132,709 | 2015-03-13 | ||
| EP15305830.0 | 2015-05-29 | ||
| EP15305830 | 2015-05-29 | ||
| PCT/US2015/040765 WO2016011260A1 (en) | 2014-07-16 | 2015-07-16 | Methods for treating high cardiovascular risk patients with hypercholesterolemia |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| RU2017104799A RU2017104799A (en) | 2018-08-16 |
| RU2017104799A3 true RU2017104799A3 (en) | 2019-02-19 |
| RU2723018C2 RU2723018C2 (en) | 2020-06-08 |
Family
ID=53365943
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2017104799A RU2723018C2 (en) | 2014-07-16 | 2015-07-16 | Methods of treating patients with a high risk of cardiovascular diseases having hypercholesterolemia |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US20160137746A1 (en) |
| EP (2) | EP3169362B1 (en) |
| JP (1) | JP6912374B2 (en) |
| KR (3) | KR102482375B1 (en) |
| CN (2) | CN114306592A (en) |
| AU (1) | AU2015289617B2 (en) |
| CA (1) | CA2955304C (en) |
| MX (2) | MX378872B (en) |
| PL (1) | PL3169362T3 (en) |
| RU (1) | RU2723018C2 (en) |
| WO (1) | WO2016011260A1 (en) |
| ZA (1) | ZA201700196B (en) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO3672B1 (en) | 2008-12-15 | 2020-08-27 | Regeneron Pharma | High Affinity Human Antibodies to PCSK9 |
| US20130064834A1 (en) | 2008-12-15 | 2013-03-14 | Regeneron Pharmaceuticals, Inc. | Methods for treating hypercholesterolemia using antibodies to pcsk9 |
| AU2012210481B2 (en) | 2011-01-28 | 2017-05-18 | Sanofi Biotechnology | Pharmaceutical compositions comprising human antibodies to PCSK9 |
| AR087305A1 (en) | 2011-07-28 | 2014-03-12 | Regeneron Pharma | STABILIZED FORMULATIONS CONTAINING ANTI-PCSK9 ANTIBODIES, PREPARATION METHOD AND KIT |
| WO2013039969A1 (en) | 2011-09-16 | 2013-03-21 | Regeneron Pharmaceuticals, Inc. | METHODS FOR REDUCING LIPOPROTEIN(a) LEVELS BY ADMINISTERING AN INHIBITOR OF PROPROTEIN CONVERTASE SUBTILISIN KEXIN-9 (PCSK9) |
| US10111953B2 (en) | 2013-05-30 | 2018-10-30 | Regeneron Pharmaceuticals, Inc. | Methods for reducing remnant cholesterol and other lipoprotein fractions by administering an inhibitor of proprotein convertase subtilisin kexin-9 (PCSK9) |
| CN111920954A (en) | 2013-06-07 | 2020-11-13 | 再生元制药公司 | Methods of inhibiting atherosclerosis by administering PCSK9 inhibitors |
| CN106062003A (en) | 2013-11-12 | 2016-10-26 | 赛诺菲生物技术公司 | Dosing regimens for use with pcsk9 inhibitors |
| KR20230074283A (en) | 2014-07-16 | 2023-05-26 | 사노피 바이오테크놀로지 | METHODS FOR TREATING PATIENTS WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA(heFH) |
| EP3197492A1 (en) * | 2014-09-23 | 2017-08-02 | Pfizer Inc | Treatment with anti-pcsk9 antibodies |
| JP2018523684A (en) | 2015-08-18 | 2018-08-23 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | Anti-PCSK9 inhibitory antibody for treating hyperlipidemic patients undergoing lipoprotein apheresis |
| MX2018010401A (en) | 2016-03-03 | 2019-03-06 | Regeneron Pharma | Methods for treating patients with hyperlipidemia by administering a pcsk9 inhibitor in combination with an angptl3 inhibitor. |
| TW201904608A (en) * | 2017-06-09 | 2019-02-01 | 法商賽諾菲生物技術公司 | Method for treating hyperlipemia in diabetic patients by administering PCSK9 inhibitor |
| WO2019173530A1 (en) * | 2018-03-06 | 2019-09-12 | Sanofi Biotechnology | Use of pcsk9 inhibitor for reducing cardiovascular risk |
| JP2023501745A (en) * | 2019-11-18 | 2023-01-18 | エーディー ファーマシューティカルズ カンパニー，リミティド | Anti-PCSK9 antibody and uses thereof |
| CA3188213A1 (en) * | 2020-08-07 | 2022-02-10 | Robert C. Pordy | Methods for treating refractory hypercholesterolemia involving an angptl3 inhibitor |
| CN116983434B (en) * | 2023-09-28 | 2024-03-15 | 康霖生物科技（杭州）有限公司 | Nucleic acid constructs for gene therapy and uses thereof |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| JO3672B1 (en) * | 2008-12-15 | 2020-08-27 | Regeneron Pharma | High Affinity Human Antibodies to PCSK9 |
| AU2012210481B2 (en) * | 2011-01-28 | 2017-05-18 | Sanofi Biotechnology | Pharmaceutical compositions comprising human antibodies to PCSK9 |
| JOP20200043A1 (en) * | 2011-05-10 | 2017-06-16 | Amgen Inc | Ways to treat or prevent cholesterol disorders |
| US20130006482A1 (en) * | 2011-06-30 | 2013-01-03 | Ramadev Burigsay Hukkeri | Guidance system for a mobile machine |
| WO2013039969A1 (en) * | 2011-09-16 | 2013-03-21 | Regeneron Pharmaceuticals, Inc. | METHODS FOR REDUCING LIPOPROTEIN(a) LEVELS BY ADMINISTERING AN INHIBITOR OF PROPROTEIN CONVERTASE SUBTILISIN KEXIN-9 (PCSK9) |
| EP2706070A1 (en) * | 2012-09-06 | 2014-03-12 | Sanofi | Combination treatments involving antibodies to human PCSK9 |
| EP4403213A3 (en) * | 2014-03-17 | 2024-10-23 | Sanofi Biotechnology | Methods for reducing cardiovascular risk |
-
2015
- 2015-07-16 KR KR1020177004219A patent/KR102482375B1/en active Active
- 2015-07-16 EP EP15760317.6A patent/EP3169362B1/en active Active
- 2015-07-16 CN CN202111397525.XA patent/CN114306592A/en active Pending
- 2015-07-16 RU RU2017104799A patent/RU2723018C2/en active
- 2015-07-16 KR KR1020227045465A patent/KR20230007538A/en not_active Ceased
- 2015-07-16 MX MX2017000628A patent/MX378872B/en unknown
- 2015-07-16 CA CA2955304A patent/CA2955304C/en active Active
- 2015-07-16 PL PL15760317T patent/PL3169362T3/en unknown
- 2015-07-16 US US14/801,392 patent/US20160137746A1/en not_active Abandoned
- 2015-07-16 EP EP20174278.0A patent/EP3753575A1/en not_active Withdrawn
- 2015-07-16 JP JP2017502259A patent/JP6912374B2/en active Active
- 2015-07-16 WO PCT/US2015/040765 patent/WO2016011260A1/en not_active Ceased
- 2015-07-16 CN CN201580049703.6A patent/CN107106678A/en active Pending
- 2015-07-16 KR KR1020247028498A patent/KR20240132123A/en not_active Ceased
- 2015-07-16 AU AU2015289617A patent/AU2015289617B2/en active Active
-
2017
- 2017-01-10 ZA ZA2017/00196A patent/ZA201700196B/en unknown
- 2017-01-13 MX MX2021000289A patent/MX2021000289A/en unknown
-
2019
- 2019-10-24 US US16/662,313 patent/US20200255544A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| ZA201700196B (en) | 2024-09-25 |
| EP3169362A1 (en) | 2017-05-24 |
| RU2723018C2 (en) | 2020-06-08 |
| PL3169362T3 (en) | 2020-12-28 |
| MX378872B (en) | 2025-03-11 |
| KR20170028441A (en) | 2017-03-13 |
| KR20240132123A (en) | 2024-09-02 |
| MX2017000628A (en) | 2017-04-27 |
| CA2955304C (en) | 2023-12-12 |
| JP2017522316A (en) | 2017-08-10 |
| MX2021000289A (en) | 2021-03-31 |
| KR102482375B1 (en) | 2022-12-29 |
| RU2017104799A (en) | 2018-08-16 |
| CA2955304A1 (en) | 2016-01-21 |
| CN107106678A (en) | 2017-08-29 |
| CN114306592A (en) | 2022-04-12 |
| EP3753575A1 (en) | 2020-12-23 |
| US20200255544A1 (en) | 2020-08-13 |
| US20160137746A1 (en) | 2016-05-19 |
| JP6912374B2 (en) | 2021-08-04 |
| AU2015289617B2 (en) | 2021-04-15 |
| WO2016011260A1 (en) | 2016-01-21 |
| AU2015289617A1 (en) | 2017-02-02 |
| KR20230007538A (en) | 2023-01-12 |
| EP3169362B1 (en) | 2020-06-10 |